February 13, 2018 / 9:13 PM / 9 months ago

BRIEF-Tetraphase Posts Top-Line Results From IGNITE3 Phase 3 Clinical Trial Of Eravacycline In CUTI

Feb 13 (Reuters) - Tetraphase Pharmaceuticals Inc:

* TETRAPHASE ANNOUNCES TOP-LINE RESULTS FROM IGNITE3 PHASE 3 CLINICAL TRIAL OF ERAVACYCLINE IN COMPLICATED URINARY TRACT INFECTIONS (CUTI)

* TETRAPHASE PHARMACEUTICALS INC - ‍ERAVACYCLINE DID NOT ACHIEVE CO-PRIMARY ENDPOINTS IN CUTI TRIAL​

* TETRAPHASE PHARMACEUTICALS INC - ‍ERAVACYCLINE WAS WELL TOLERATED IN IGNITE3​

* TETRAPHASE - ‍CONTINUES TO PREPARE FOR COMMERCIALIZATION OF ERAVACYCLINE AS A TREATMENT FOR CIAI IN U.S. AND EUROPE, ASSUMING REGULATORY APPROVAL​

* TETRAPHASE PHARMACEUTICALS INC - ‍CONTINUE TO MOVE FORWARD WITH OUR REGISTRATION STRATEGY FOR ERAVACYCLINE IN COMPLICATED INTRA-ABDOMINAL INFECTIONS​

* TETRAPHASE PHARMACEUTICALS- STUDY FAILED TO MEET CO-PRIMARY EFFICACY ENDPOINTS OF RESPONDER RATE IN MICRO-ITT POPULATION AT EOI TREATMENT VISIT, TOC VISIT Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below